概述《癌癥科學》(原日本癌癥研究雜志)的目標是提出對腫瘤學家具有重大臨床影響或可能改變腫瘤疾病概念的研究。該雜志發表原創文章和社論，給編輯的信件，評論文章和報告，描述在基礎，轉化和臨床癌癥領域的原創研究。學科類別包括:基礎免疫學和臨床免疫學致癌作用細胞、分子和干細胞生物學臨床研究藥物發現及運送流行病學和預防遺傳學、基因組學和蛋白質組學炎癥和病毒學病理學目標和范圍《癌癥科學》(原日本癌癥研究雜志)是日本癌癥協會的月刊。該雜志于1907年首次出版，繼續發表原創文章、社論和給編輯的信件，描述基礎、轉化和臨床癌癥研究領域的原創研究。該雜志還接受報告和病例報告。癌癥科學的目標是提出非常重要和及時的發現，對腫瘤學家有重要的臨床影響，或可能改變腫瘤的疾病概念。如果沒有新的發現可以添加到以前的報告中，該雜志將不會發表描述罕見腫瘤或疾病的病例報告;不同腫瘤的組合，沒有新的腫瘤學研究提示發現;在沒有提示數據來解釋異常結果的情況下，已經知道的治療效果顯著。評審文章也可以發表。從2017年1月1日起，癌癥科學將不接受任何煙草行業資助的工作。第一次決定的平均提交時間是17天!讀者提供進入日本領先的腫瘤學會的成員，有16000名成員關鍵字腫瘤，癌癥，日本癌癥協會，癌癥科學，癌癥研究，姑息治療，放射治療抽象和索引信息農業生物科技新聞與信息(CABI)生物酶:當前生物科學的認識(愛思唯爾)生物文摘(Clarivate Analytics)生物預覽(Clarivate Analytics)CAS:化學文摘服務(ACS)CSA生物科學數據庫(ProQuest)CSA致癌基因與生長因子摘要(ProQuest)目前內容:臨床醫學(科萊恩分析)Embase(愛思唯爾)注意:健康經濟評估數據庫(Wiley-Blackwell)InfoTrac(蓋爾Cengage)期刊引用報告/科學版(Clarivate Analytics)MEDLINE / PubMed (NLM)PubMed膳食補充劑子集(NLM)科學引文索引(Clarivate Analytics)科學引文索引擴展(Clarivate Analytics)斯高帕斯(愛思唯爾)

OverviewCancer Science (formerly Japanese Journal of Cancer Research) aims to present research that has a significant clinical impact on oncologists or that may alter the disease concept of a tumor. The Journal publishes original articles and editorials, letters to the editor, review articles and reports describing original research in the fields of basic, translational and clinical cancer. Subject categories include: Basic and Clinical Immunology Carcinogenesis Cell, Molecular, and Stem Cell Biology Clinical Research Drug Discovery and Delivery Epidemiology and Prevention Genetics, Genomics, and Proteomics Inflammation and Virology PathologyAims and ScopeCancer Science (formerly Japanese Journal of Cancer Research) is a monthly publication of the Japanese Cancer Association. First published in 1907, the Journal continues to publish original articles, editorials, and letters to the editor, describing original research in the fields of basic, translational and clinical cancer research. The Journal also accepts reports and case reports.Cancer Science aims to present highly significant and timely findings that have a significant clinical impact on oncologists or that may alter the disease concept of a tumor. The Journal will not publish case reports that describe a rare tumor or condition without new findings to be added to previous reports; combination of different tumors without new suggestive findings for oncological research; remarkable effect of already known treatments without suggestive data to explain the exceptional result. Review articles may also be published.Effective from 1 January 2017, Cancer Science will not accept work that is funded in any part by tobacco industry sources.Average submission to first decision is 17 days!ReadershipOffers access to members of Japan''''''''s leading oncology society, with 16,000 membersKeywordsoncology, cancer, Japanese Cancer Association, Cancer Science, cancer research, palliative care, radiotherapyAbstracting and Indexing Information AgBiotech News & Information (CABI) BIOBASE: Current Awareness in Biological Sciences (Elsevier) Biological Abstracts (Clarivate Analytics) BIOSIS Previews (Clarivate Analytics) CAS: Chemical Abstracts Service (ACS) CSA Biological Sciences Database (ProQuest) CSA Oncogenes & Growth Factors Abstracts (ProQuest) Current Contents: Clinical Medicine (Clarivate Analytics) Embase (Elsevier) HEED: Health Economic Evaluations Database (Wiley-Blackwell) InfoTrac (GALE Cengage) Journal Citation Reports/Science Edition (Clarivate Analytics) MEDLINE/PubMed (NLM) PubMed Dietary Supplement Subset (NLM) Science Citation Index (Clarivate Analytics) Science Citation Index Expanded (Clarivate Analytics) SCOPUS (Elsevier)